Neonatal BCG vaccination and tuberculin skin sensitivity among schoolchildren of the United Arab Emirates.

Ann Trop Paediatr

Department of Paediatrics, Faculty of Medicine & Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.

Published: December 1996

A cross-sectional survey of 785 schoolchildren living in the Al Ain region was undertaken between January and June 1994 to assess the effect of neonatal BCG vaccination on tuberculin sensitivity and to study the risk of exposure to tuberculosis in the same population. A documented history of BCG vaccination was obtained in 547 (69.7%) schoolchildren. The prevalence of a 10 mm or greater induration of tuberculin skin reactivity varied from 8% in unvaccinated to 11.5% among vaccinated children. This was not statistically significant. Children living in urban areas irrespective of vaccination status had a higher rate of tuberculin reactivity than those living in rural areas (relative risk 5.77; 95% confidence interval 1.85-18.00; p < 0.0004). The pattern and rate of tuberculin sensitivity were similar among the other socio-demographic standards investigated. Earlier BCG vaccination had no effect on subsequent tuberculin sensitivity of either negative (0.4 mm), intermediate (5-9 mm) or positive (> or = 10 mm) type skin reactions. It is concluded that the risk of exposure to tuberculous infection is several times higher among children living in urban areas than among those living in a rural environment. Earlier BCG vaccination should not interfere with diagnostic tuberculin skin sensitivity and is still a useful tool in assessing the risk of tuberculous infection in such populations.

Download full-text PDF

Source
http://dx.doi.org/10.1080/02724936.1996.11747850DOI Listing

Publication Analysis

Top Keywords

bcg vaccination
20
tuberculin skin
12
tuberculin sensitivity
12
neonatal bcg
8
vaccination tuberculin
8
skin sensitivity
8
risk exposure
8
children living
8
living urban
8
urban areas
8

Similar Publications

Long-term evaluation in BALBc mice of a triple mutant of Mycobacterium bovis and the Bacillus Calmette-Guérin as potential vaccines against bovine tuberculosis.

Vet Microbiol

January 2025

Instituto de Agrobiotecnología y Biología Molecular, (IABIMO) INTA-CONICET, Argentina; Instituto de Biotecnología, CICVyA, Instituto Nacional de Tecnología Agropecuaria, N. Repetto and De los Reseros, Hurlingham, Buenos Aires 1686, Argentina. Electronic address:

There is currently no commercial vaccine available against bovine tuberculosis (bTB). Mycobacterium bovis is the primary causative agent of bTB and is closely related to Mycobacterium tuberculosis, the pathogen responsible for human TB. Despite their limitations, mouse models are invaluable in early vaccine development due to their genetic diversity, cost-effectiveness, and the availability of research tools.

View Article and Find Full Text PDF

Background: Pulmonary tuberculosis (PTB) accounts for 85% of all reported tuberculosis cases globally. Extrapulmonary involvement can occur in isolation or along with a pulmonary focus as in the case of patients with disseminated tuberculosis (TB). EPTB can occur through hematogenous, lymphatic, or localized bacillary dissemination from a primary source, such as PTB and affects the brain, eye, mouth, tongue, lymph nodes of neck, spine, bones, muscles, skin, pleura, pericardium, gastrointestinal, peritoneum and the genitourinary system as primary and/or disseminated disease.

View Article and Find Full Text PDF

Today's controversies of gain-of-function virological research and mRNA COVID vaccination policies had an antecedent nearly a century ago in an event often referred to as "the Lübeck disaster." From April through September 1930, 77 newborn infants in Lübeck, Germany, died after receiving oral BCG immunizations tainted with active human . The tragedy threatened to end BCG immunizations.

View Article and Find Full Text PDF

Protection against tuberculosis by vaccination of secreted chorismate mutase (Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and alum adjuvants.

Vaccine

January 2025

Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Cancer Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Seoul National University Medical Research Center (SNUMRC), Seoul 03080, Republic of Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; Liver Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea; BK21 FOUR Biomedical Science Project, Seoul National University College of Medicine, Seoul 03080, Republic of Korea. Electronic address:

Tuberculosis (TB) remains a significant global health issue due to the limited efficacy of the Bacillus Calmette-Guérin (BCG) vaccine, highlighting the need for the development of an improved TB vaccine. In this study, we created a novel TB subunit vaccine consisting of TB-secreted chorismate mutase (TBCM) (Rv1885c) and a hepatitis B virus (HBV)-derived peptide (Poly6), which elicits Type I interferon responses, both with and without an alum adjuvant. We evaluated the immunogenicity, protective efficacy, and therapeutic efficacy of this vaccine candidate in an in vivo mouse model.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!